The selective allosteric ABL1 inhibitor ABL001 (asciminib) represents a new inhibitory mechanism for BCR–ABL1-driven malignancies, and its efficacy and evolving mechanisms of resistance do not overlap with those of other BCR–ABL1 kinase inhibitors.
Dual targeting of gene fusion
Current inhibitors targeting the BCR–ABL1 mutation have saved man...

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

10.1038/nature21702